This newsletter presents you the following key sessions:
1. PODCAST with dr. Lisa Salvatore about the primary analysis results of the phase II AVANA study, which
evaluated preoperative chemoradiotherapy, combined with avelumab, in patients with locally advanced
rectal cancer
2. Pembrolizumab plus trastuzumab and chemotherapy as first-line treatment for unresectable or metastatic
HER2-positive gastric or GEJ adenocarcinoma
3. Clinically meaningful survival advantage with 177Lu-DOTATATE in advanced midgut neuroendocrine
tumours
4. No benefit from adding napabucasin to FOLFIRI in patients with previously treated metastatic colorectal
cancer
5. Impact of FGFR2-rearrangements in treatment response to systemic therapies in cholangiocarcinoma